Skip to main content
SpringerLink
Log in

Fulvestrant

Various toxicities: 4 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The patient demographics have been obtained though direct communication with the Author.

Reference

  • Zhao Y, et al. Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer. Cancer Medicine 9: 8821-8831, No. 23, Dec 2020. Available from: URL: https://doi.org/10.1002/cam4.3491

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fulvestrant. Reactions Weekly 1840, 197 (2021). https://doi.org/10.1007/s40278-021-90340-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-90340-2

Search

Navigation